A Phase 1, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Intravenous and Subcutaneous Single-Dose Study in Healthy Subjects and Ascending Subcutaneous Multiple-Dose Study in Subjects With Type 2 Diabetes Mellitus to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immune Response of CNTO 3649
Phase of Trial: Phase I
Latest Information Update: 13 Dec 2013
At a glance
- Drugs CNTO 3649 (Primary) ; CNTO 3649 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- 15 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Jul 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.
- 08 Jul 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.